Xalkori Development Timeline
This article was originally published in Pharmaceutical Approvals Monthly
A chronology of significant events in the regulatory review process for Pfizer’s oncologic.
You may also be interested in...
The German major's two leading products continue to perform well but there are not many potential blockbusters in the pipeline.
Analysts forecast a slow climb towards peak sales of $2bn – but competitors could erode that figure.